{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:50:11Z","timestamp":1791474611739,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016694","name":"Science and Technology Development Plan of Shandong Province","doi-asserted-by":"publisher","award":["2019-0114"],"award-info":[{"award-number":["2019-0114"]}],"id":[{"id":"10.13039\/100016694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016350","name":"Sichuan Provincial Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020206","name":"Shandong Provincial Health Commission","doi-asserted-by":"publisher","award":["2022-93"],"award-info":[{"award-number":["2022-93"]}],"id":[{"id":"10.13039\/501100020206","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.heliyon.2024.e37348","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T14:58:41Z","timestamp":1725634721000},"page":"e37348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Sorafenib safety evaluation: Real-world analysis of adverse events from the FAERS database"],"prefix":"10.1016","volume":"10","author":[{"given":"Lin","family":"Ning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanyue","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2074-7713","authenticated-orcid":false,"given":"Jianguang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.heliyon.2024.e37348_bib1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","article-title":"Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070","volume":"18","author":"Soerjomataram","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e37348_bib2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e37348_bib3","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e37348_bib4","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1245\/s10434-022-12151-6","article-title":"GLOBOCAN 2020 report on global cancer burden: challenges and opportunities for surgical oncologists","volume":"29","author":"Deo","year":"2022","journal-title":"Ann. Surg Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e37348_bib5","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1158\/1055-9965.EPI-22-1133","article-title":"Recent mortality patterns and time trends for the major cancers in 47 countries worldwide","volume":"32","author":"Sedeta","year":"2023","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e37348_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17425255.2023.2277758","article-title":"Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics","volume":"19","author":"Sarah","year":"2023","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37348_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37348_bib8","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2077898","article-title":"Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy","volume":"11","author":"Petrazzuolo","year":"2022","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37348_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-018-0800-6","article-title":"Targeting tumour microenvironment by tyrosine kinase inhibitor","volume":"17","author":"Tan","year":"2018","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e37348_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112798","article-title":"Emerging therapies for hepatocellular carcinoma (HCC)","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37348_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37348_bib12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2024.e37348_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113690","article-title":"Treatment for liver cancer: from sorafenib to natural products","volume":"224","author":"Man","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"10408","key":"10.1016\/j.heliyon.2024.e37348_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.heliyon.2024.e37348_bib15","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for advanced and refractory desmoid tumors","volume":"379","author":"Gounder","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e37348_bib16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bcpt.12365","article-title":"The adverse effects of sorafenib in patients with advanced cancers","volume":"116","author":"Li","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e37348_bib17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/1759-7714.12608","article-title":"Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors","volume":"9","author":"Fu","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.heliyon.2024.e37348_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1039121","article-title":"The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"9","author":"Guven","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e37348_bib19","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00262-023-03366-x","article-title":"Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study","volume":"72","author":"Rizzo","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e37348_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12111788","article-title":"Trans-arterial chemoembolization plus systemic treatments for hepatocellular carcinoma: an update","volume":"12","author":"Rizzo","year":"2022","journal-title":"J. Personalized Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e37348_bib21","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","article-title":"Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study","volume":"17","author":"Rizzo","year":"2021","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"9940","key":"10.1016\/j.heliyon.2024.e37348_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e37348_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/14740338.2023.2152793","article-title":"Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis","volume":"22","author":"Rizzo","year":"2023","journal-title":"Expet Opin. Drug Saf."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e37348_bib24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37348_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e37348_bib26","first-page":"1","article-title":"Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS)","author":"Wen","year":"2024","journal-title":"Expet Opin. Drug Saf."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e37348_bib27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e37348_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17512433.2024.2306223","article-title":"Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022","volume":"17","author":"Du","year":"2024","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e37348_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e37348_bib30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e37348_bib31","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e37348_bib32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf."},{"issue":"30","key":"10.1016\/j.heliyon.2024.e37348_bib33","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1002\/sim.8745","article-title":"Extended multi-item gamma Poisson shrinker methods based on the zero-inflated Poisson model for postmarket drug safety surveillance","volume":"39","author":"Heo","year":"2020","journal-title":"Stat. Med."},{"key":"10.1016\/j.heliyon.2024.e37348_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.667798","article-title":"Effects of sorafenib, a tyrosin kinase inhibitor, on adrenocortical cancer","volume":"12","author":"Cerquetti","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.heliyon.2024.e37348_bib35","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ejmech.2019.06.070","article-title":"Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma","volume":"179","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"10126","key":"10.1016\/j.heliyon.2024.e37348_bib36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37348_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e37348_bib38","article-title":"Camrelizumab plus sorafenib versus sorafenib monotherapy for advanced hepatocellular carcinoma: a retrospective analysis","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"issue":"27","key":"10.1016\/j.heliyon.2024.e37348_bib39","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37348_bib40","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1038\/s41598-020-66583-9","article-title":"Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters","volume":"10","author":"Hsieh","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e37348_bib41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr. Drug Metabol."},{"issue":"Pt 2","key":"10.1016\/j.heliyon.2024.e37348_bib42","article-title":"The influence of sunitinib and sorafenib, two tyrosine kinase inhibitors, on development and thyroid system in zebrafish larvae","volume":"308","author":"Wei","year":"2022","journal-title":"Chemosphere"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e37348_bib43","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e37348_bib44","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/cam4.3674","article-title":"Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: a phase II, randomized study","volume":"10","author":"Haruna","year":"2021","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e37348_bib45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3748\/wjg.v28.i2.216","article-title":"Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma","volume":"28","author":"Hanif","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e37348_bib46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-4598-8-27","article-title":"Identification of the B-Raf\/Mek\/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion","volume":"8","author":"Cheepala","year":"2009","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e37348_bib47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11523-023-00951-z","article-title":"Analysis of anti-angiogenesis-related adverse events associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in patients with metastatic renal cell carcinoma","volume":"18","author":"Lee","year":"2023","journal-title":"Targeted Oncol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024133798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024133798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:36:52Z","timestamp":1790714212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024133798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":47,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2405844024133798"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37348","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib safety evaluation: Real-world analysis of adverse events from the FAERS database","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e37348"}}